Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...